LDK-378, ALK inhibitor

Min.Order / FOB Price:Get Latest Price

0 Metric Ton	Negotiable

0 Metric Ton

Negotiable

Min.Order :0 Metric Ton
Purity: 99

Keywords

1032900-25-6

Quick Details

Appearance:
Application:
PackAge:
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:

Superiority:

All our products are in stock at our US office. Get fastest quotation, please visit www.activebiochem.com, thanks.

Details:

More information, please Biological Activity

LDK-378 is the second generation of ALK inhibitor which shows substantial clinical activity in patients with ALK-positive non-small cell lung cancer (NSCLC), with an overall response rate of 81% in patients previously treated with the US FDA approved ALK inhibitor crizotinib (PF-02341066).

LDK-378 targets ALK, a key gene implicated in the development of some lung cancers, lymphomas, and childhood neuroblastomas. Approximately 6-8% of all NSCLCs are ALK-positive; these cancers are more likely to affect nonsmokers and younger individuals. LDK378 is a selective ALK inhibitor that has demonstrated enhanced potency over crizotinib and noteworthy antitumor activity in preclinical models, including in crizotinib-resistant tumors.

View All

Visit Store